3020.9000 2.20 (0.07%)
NSE May 23, 2025 15:31 PM
Volume: 101.3K
 

3020.90
0.07%
Karvy
Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.
GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended